

# MENTAL HEALTHCARE IS ABOUT TO CHANGE FOR THE BETTER

July 2026

## Dear Prospective Supporter

After decades of research, psychedelic medicines are moving toward FDA approval for multiple mental health conditions. The field is now shifting from discovery to implementation. Building the clinical infrastructure needed to responsibly deliver these therapies at scale is the mission of *Psychedelic Science Institute (PSI)*.

PSI was founded by leaders in neuroscience, addiction medicine, psychology, psychedelic medicine, and healthcare strategy.

## IN JUST ONE YEAR, WE HAVE

- **Opened two clinics in Hollywood and Santa Monica**
- **Enrolled patients in eight clinical trials for anxiety and depression**
- **Delivered over 550 Ketamine-Assisted Psychotherapy sessions**
- **Launched development of a technology platform for compliant delivery of psychedelic medicines**
- **Established one of Southern California's leading psychedelic clinical care & research programs**

## THE PSYCHEDELIC INNOVATION FUND

The Psychedelic Innovation Fund (PIF) is PSI's philanthropic partner enabling PSI to invest in the people, technology, and innovation that cannot be fully supported through clinical revenue or industry-sponsored research. Since founding PIF in late 2024, we have raised over \$2M in philanthropy. We are now seeking an additional \$600,000 in philanthropy by year-end to expand our clinical and research capabilities, further develop our care platform, and prepare for the first FDA-approved psychedelic therapies.

## WHY PHILANTHROPY MATTERS

While clinical trial and patient care revenue continue to grow, additional funding will allow PSI to pursue its mission: to advance the science and build the care delivery model that brings psychedelic medicines and related neuroplasticity-based therapies safely and equitably into mainstream healthcare.

### WAYS TO GIVE

#### Individuals

- **Traditional Philanthropic Donation to PIF:**  
tax-deductible, no financial return
- **Donor Advised Fund (DAF) Distribution to PIF:**  
direct your DAF to make a grant to PIF
- **DAF Investment into PSI (potential for ROI):**  
utilize your existing DAF or establish a new DAF

#### Foundations

- **Standard Foundation Grant to PIF:**  
credit towards 5% requirement, no financial return.
- **Recoverable Grant (potential for ROI):**  
via PIF investment into PSI (SAFE note with 20% discount)

## AN INVITATION TO PARTNERSHIP

We are grateful for your consideration in helping build the future of mental healthcare. Please see below for more information.


Sincerely,



**Daniel F. Kelly, MD**  
Chief Executive Officer  
dkelly@psychedelicsci.com



**Gregory Kearns, MHA**  
Chief Strategy & Business  
Development Officer  
gkearns@psychedelicsci.com



**Mike Avila**  
Philanthropic Advisor  
mavila@psychedelicsci.com

## MENTAL HEALTHCARE IS ABOUT TO CHANGE FOR THE BETTER

Recent policy initiatives, encouraging late-stage clinical trial results, and growing scientific consensus have accelerated momentum toward FDA approvals for psychedelic medicines like psilocybin, LSD, and MDMA. As these therapies move toward implementation, the next challenge is building the clinical infrastructure to deliver them safely, responsibly, and at scale.

PSI is building that infrastructure by integrating specialized care delivery, clinical trials, technology, clinician training, and health system partnerships into a scalable platform.

### WHY THESE THERAPIES ARE DIFFERENT

#### **Psychedelics are potent neuroplastogens**

Unlike conventional psychiatric medications that are typically taken daily, psychedelic medicines promote rapid neuroplasticity and durable changes in brain networks. When combined with structured mental health care, many patients have meaningful and lasting improvements after only 1–3 monitored treatment sessions.

#### **They are safe in controlled settings**

More than two decades of modern clinical research have shown that psychedelic medicines, including psilocybin, LSD, and MDMA, are safe and have minimal to no addictive potential when delivered in structured settings with trained medical supervision.

[Learn About our Clinical Trials at PSI TRIP Clinics.](#)

### LIKELY INITIAL CLINICAL APPLICATIONS

- Depression
- Anxiety
- Addiction
- PTSD
- Grief & existential distress

### POSSIBLE FUTURE USES

- Traumatic brain injury
- Stroke recovery
- Cognitive decline & dementia
- Parkinson's disease
- Chronic pain

#### **Your gift or grant helps PSI**

- Advance the future of mental healthcare
- Prepare for the first FDA-approved therapies
- Expand patient access through research, education & innovation

## JOIN US IN BUILDING THE FUTURE OF MENTAL HEALTHCARE



**Daniel Kelly, MD**  
CHIEF EXECUTIVE  
OFFICER



**Keith Heinzerling, MD**  
CHIEF MEDICAL &  
SCIENCE OFFICER



**Brooke Balliett, LMFT**  
CHIEF OPERATING  
OFFICER



**Micah Linton, PsyD**  
CHIEF CLINICAL &  
INNOVATION OFFICER



**Greg Kearns, MHA**  
CHIEF STRATEGY  
& BUSINESS  
DEVELOPMENT  
OFFICER